key: cord-0821250-1rjos7pb
authors: Temesgen, Zelalem; Assi, Mariam; Shweta, F.N.U.; Vergidis, Paschalis; Rizza, Stacey A.; Bauer, Philippe R.; Pickering, Brian W.; Razonable, Raymund R.; Libertin, Claudia R.; Burger, Charles D.; Orenstein, Robert; Vargas, Hugo E.; Palraj, Raj; Dababneh, Ala S.; Chappell, Gabrielle; Chappell, Dale; Ahmed, Omar; Sakemura, Reona; Durrant, Cameron; Kenderian, Saad S.; Badley, Andrew D.
title: GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study
date: 2020-09-03
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.08.038
sha: 625340d61a42702d921f83b9a2abd4b26ed51041
doc_id: 821250
cord_uid: 1rjos7pb
Objective To assess the efficacy and safety of lenzilumab in patients with severe COVID-19 pneumonia. Methods Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use investigational new drug application. Patient characteristics, clinical and laboratory outcomes, and adverse events were recorded. We also identified a cohort of patients matched to the lenzilumab patients for age, gender, and disease severity. Study dates were March 13, 2020 to June 18, 2020. All patients were followed through hospital discharge or death. Results Twelve patients were treated with lenzilumab; 27 patients comprised the matched control cohort (untreated). Clinical improvement, defined as improvement of at least 2 points on the 8-point ordinal clinical endpoints scale, was observed in 11 out of 12 (92%) lenzilumab treated patients and 22 out of 27 (81%) untreated patients. The time to clinical improvement was significantly shorter for lenzilumab-treated group compared to the untreated cohort: median 5 days vs. 11 days (P = .006). Similarly, the proportion of patients with acute respiratory distress syndrome (ARDS) (SpO2/FiO2 < 315) was significantly reduced over time when treated with lenzilumab compared to untreated (P < .001). Significant improvement in inflammatory markers (C-Reactive Protein, interleukin 6) and markers of disease severity (absolute lymphocyte count) were observed in patients who received lenzilumab, but not in untreated patients. Cytokine analysis showed a reduction in inflammatory myeloid cells two days after lenzilumab treatment. There were no treatment-emergent adverse events attributable to lenzilumab. Conclusions In high-risk COVID-19 patients with severe pneumonia, GM-CSF neutralization with lenzilumab was safe and associated with faster improvement in clinical outcomes, including oxygenation, and greater reductions in inflammatory markers compared to a matched control cohort of patients hospitalized with severe COVID-19 pneumonia. A randomized, placebo controlled clinical trial to validate these findings is ongoing (NCT04351152).
The clinical manifestations of COVID-19, the disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) infection, range from asymptomatic disease to severe pneumonia.
(1, 2) Although viral evasion of host immune response and virus-induced cytopathic effects are believed to be critical for disease progression, most deaths associated with COVID-19 are attributed to the development of an immune hyper-response and resultant acute respiratory distress syndrome (ARDS) and multi-organ failure. (3) The immune hyper-response is characterized by an elevation of inflammatory cytokines resulting in fever, hypotension, capillary leak syndrome, pulmonary edema, disseminated intravascular coagulation, respiratory failure, and ARDS. (4, 5) A similar immune hyperstimulation has been previously described in patients with autoimmune and lymphoproliferative diseases, (6) as well as in patients with B-cell malignancies receiving chimeric antigen receptor T-cell (CART) therapy, and has been named cytokine release syndrome (CRS). (7, 8) Over the last five years, preclinical studies and correlative science from clinical trials in CART therapy have shed light on the pathophysiology, development, characterization, and management of CRS. (5, 9) CRS during CART therapy is characterized by activation of myeloid cells and release of inflammatory cytokines and chemokines, including interleukin-6 (IL-6), granulocyte-monocyte colony stimulating factor (GM-CSF), monocyte chemoattractant protein -1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α), Interferon gamma-induced protein 10 (IP-10), and interleukin-1 (IL-1). (4, 7, 10) The cascade, once initiated, can quickly evolve into a cytokine storm, resulting in further activation, expansion and trafficking of myeloid cells, leading to abnormal endothelial activation, increased vascular permeability, and disseminated intravascular coagulation. (11, 12) Similar to CRS in patients receiving CART therapy, the immune hyper-response in patients with COVID-19 has been associated with elevation of C-reactive protein (CRP), ferritin, and IL-6, as well as correlating with respiratory failure, ARDS, and adverse clinical outcomes. (13) (14) (15) (16) (17) Most significantly, high levels of GM-CSF-secreting T-cells (Th GM cells) have been associated with disease severity, myeloid cell trafficking to the lungs, and ICU admission. (18) The elevation in inflammatory cytokine levels indicates that post-COVID-19 immune hyperstimulation is caused by a similar mechanism, induced by activation of myeloid cells and their trafficking to the lung, resulting in lung injury and ARDS. (18) Tissue CD14+ myeloid cells produce GM-CSF and IL-6, further triggering a cytokine storm cascade. (18) Single-cell RNA sequencing of bronchoalveolar lavage samples from COVID-19 patients with severe ARDS demonstrated an overwhelming infiltration of newly-arrived inflammatory myeloid cells compared to mild COVID-19 disease and healthy controls, consistent with a hyperinflammatory immune-mediated pathology. (19) With this understanding of the pathophysiology of COVID-19, modalities to target inflammatory cytokines and suppress or prevent immune hyperstimulation after COVID-19 have been investigated in pilot clinical trials. Controlled clinical trials using IL-6 blockade, as well as other immunomodulatory molecules targeting receptor tyrosine kinase are ongoing.
Our group has developed GM-CSF depletion as a strategy to mitigate CRS following CART therapy. We have shown that GM-CSF neutralization results in a reduction in IL-6, MCP-1, MIP-1α, IP-10, vascular endothelial growth factor (VEGF), and tumor necrosis factor-α (TNFα) levels, demonstrating that GM-CSF is an upstream regulator of many inflammatory Lenzilumab is a first-in-class recombinant monoclonal antibody targeting human GM-CSF, with potential immunomodulatory activity, high binding affinity in the picomolar range, 94% homology to human germline, and has low immunogenicity. Following intravenous administration, lenzilumab binds to and neutralizes GM-CSF, preventing GM-CSF binding to its receptor, thereby preventing GM-CSF-mediated signaling to myeloid progenitor cells. (22) Lenzilumab has been studied across 4 completed clinical trials in healthy volunteers, and patients with asthma, rheumatoid arthritis, and chronic myelomonocytic leukemia. (23, 24) A total of 113 individuals received lenzilumab in these trials. Lenzilumab was well tolerated with a low frequency and severity of adverse events. (23, 24) Given the hypothesized role of GM-CSF in the pathogenesis of COVID-19 related immune hyper-response, along with our studies demonstrating that GM-CSF depletion prevents CRS and modulates myeloid cell behavior in preclinical models, (20) lenzilumab therapy was offered to patients hospitalized with severe COVID-19 pneumonia, who had clinical and/or biomarker evidence for increased risk of progression to respiratory failure.
Hospitalized patients with COVID-19, confirmed by reverse transcriptase-polymerase chain reaction for the SARS-CoV-2, and radiographic findings consistent with COVID-19 pneumonia were considered for treatment with lenzilumab through an emergency investigational new drug (IND) program. Active systemic infection with bacteria, fungi, or other viruses, was an exclusion criterion. Informed consent and Institutional Review Board approval was obtained for each patient. A request for lenzilumab under FDA emergency use IND was submitted to the FDA in accordance with agency guidelines (https://www.fda.gov/regulatory-information/searchfda-guidance-documents/emergency-use-investigational-drug-or-biologic). A control cohort of patients who did not receive lenzilumab (untreated) was identified from an electronic registry of more than 1900 COVID-19 patients in the same healthcare centers as the lenzilumab-treated patients, and were matched to cases on sex and age within a tolerance of 5 years. Patients in the untreated group were further matched to patients in the lenzilumab group for disease severity (hospitalized with COVID-19 pneumonia, at least 1 risk factor for poor outcome from COVID-19, and required oxygen supplementation without mechanical ventilation). At the time of their selection for the untreated group, the clinical outcomes of these patients were not known.
Lenzilumab-treated patients (treated) received lenzilumab 600 mg administered via a 1-hour intravenous infusion every 8 hours for a total of three doses (1800 mg). Study dates were March 13, 2020 to June 18, 2020 . All patients (lenzilumab-treated and untreated) were followed through hospital discharge or death.
All laboratory tests and radiologic assessments were performed at the discretion of the treating physician and per standard clinical management processes. Vital signs were monitored before and upon completion of each lenzilumab infusion. Demographics, co-existing conditions, laboratory and radiographic data, as well as clinical data, adverse events, and outcomes were captured from the electronic health record until discharge or death. Similarly, for lenzilumab treated patients, data was collected up to the date of discharge or death. For untreated patients, baseline was considered their first day of hospitalization. Baseline values for the lenzilumab treated group were defined as those values obtained prior to lenzilumab administration, either on the day of administration for patients who receive lenzilumab on the first day of hospital admission or the day before the administration for patients that received lenzilumab after the first day of admission. Cytokine analysis was performed on serum isolated from one patient, who had samples available pre and post lenzilumab treatment. Serum was diluted 1:2 with human serum matrix before following the manufacturer's protocol for Milliplex Human Cytokine/Chemokine MAGNETIC BEAD Premixed 38 Plex Kit (Millipore Sigma, Ontario, Canada). Data were collected using a Luminex (Millipore Sigma, Ontario, Canada).
Continuous variables at baseline are represented using the median and interquartile range (IQR) and compared using a Wilcoxon rank-sum test. Proportions between groups at baseline were compared using Fischer's exact test. We were not available for more than 50% of this cohort. For the untreated cohort, first day of hospitalization was used as baseline and day 4 of hospitalization as the relevant time period to measure change from baseline. Differences in mean change between lenzilumab-treated and untreated groups were assessed for statistical significance with an independent two-sample t-test comparing baseline and last values as defined above. Differences in mean SpO2/FiO2 ratio over time between the treated and untreated groups was assessed using repeated measures ANOVA test. Proportion of patients with ARDS (SpO2/FiO2 < 315) over time between lenzilumab treated and untreated groups was assessed using repeated measures ANOVA test. Significance of proportional changes between groups was assessed by calculating the odds ratio. The time to event analyses was portrayed by Kaplan-Meier plots, and curves were compared with a log-rank test. GraphPad Prism version 8.0.0 for Windows was used to perform analysis (GraphPad Software, San Diego, California USA)
Twelve patients received full treatment with 3 doses of lenzilumab administered 8 hours apart. Twenty-seven patients comprised the matched control cohort. The baseline demographic and clinical characteristics of lenzilumab treated and untreated patients are summarized in Table 1 .
In the lenzilumab group, 5 (42%) patients received other pharmacotherapies targeting COVID-19 besides lenzilumab. Three patients received hydroxychloroquine, 1 of these also Table 2 ).
Ventilator-free survival was better in the lenzilumab cohort compared to untreated group, but did not reach statistical significance (x 2 =3.67, P = .06; Figure 1B Table 3 ). Significant increases in mean platelet count from baseline were noted among both treated and untreated groups; 52.5, P = .002 and 63.2, P < .001, respectively. However, the difference between the two groups was not statistically significant (P = .61, Table 3 ).
Lenzilumab was well-tolerated in all patients. One patient, with a history of restless leg syndrome, reported a "pins and needles" sensation during the first dose of lenzilumab; those symptoms resolved and did not recur with subsequent infusions of lenzilumab. There was no significant difference in mean absolute neutrophil count or hemoglobin values between baseline and day 4 post lenzilumab: 5.1x109/L vs. 4.8 x109/L, P = .27; 12.9 g/dL vs. 11.4 g/dL, P = .89; respectively. In one patient, hemoglobin values dropped from 10.3 g/dL on day 0 to 7.9 g/dL on day 6. This patient had undergone a renal biopsy on day 2; imaging revealed a subcapsular hematoma. At the last study observation, the patient remained anemic at 9.3 g/dL. No treatmentemergent adverse events attributable to lenzilumab were noted. These treatment decisions were not done systematically and the number of patients who received each individual therapy is so small that any meaningful analysis of their potential contribution to patients' outcomes cannot be made.
The use of lenzilumab was safe, without any adverse events attributable to lenzilumab.
Numerically, more patients in the matched cohort required mechanical ventilation or died compared to patients receiving lenzilumab. However, this was not statistically significant. While there is a theoretical concern for bone marrow toxicity when GM-CSF is depleted, lenzilumab treatment was not associated with any hematological toxicity in this cohort. There were no infusion reactions following lenzilumab treatment.
Our report has several limitations. First, the sample size is small. Second, as lenzilumab was offered under emergency single-use IND conditions, all management decisions, including prescribing medications and laboratory/radiologic monitoring, were at the discretion of the treating clinicians. There was heterogeneity in the treatment specifics of individual patients as well as the laboratory and other diagnostic data that were collected. Though we have attempted to provide context to our observations by including a matched cohort, this is not a randomized controlled clinical trial. Therefore, we cannot, with full confidence, declare that all of the clinical improvement that we observed in our patients was clearly and solely attributable to lenzilumab.
However, the better outcomes in patients who received lenzilumab compared to patients in the matched cohort are very encouraging and will be further addressed in the upcoming randomized National Institutes of Allergy and Infectious Diseases (NIAID) sponsored Big Effect Trial (BET) in addition to the Phase III clinical trial (NCT04314843) that has recently been initiated.
We administered lenzilumab, under a single-use emergency IND compassionate program, to 12 patients with severe COVID-19 pneumonia and with risk factors for disease progression.
McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatology. 2020. J o u r n a l P r e -p r o o f (4 -42) .006
Days to discharge from hospital 5 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 11 (4 -42) .008
Mean temperature reduction 1.075 0.459 .02
Days to resolution of fever 2 (1-6) 1 (1-3) .22
Incidence of IMV 1 (8%) 10 (37%) .10
Incidence of death 1 (8%) 5 (19%) .43
Incidence of IMV and/or death 1 (8%) 11 (41%) .07
J o u r n a l P r e -p r o o f Table 4 . Serum inflammatory cytokine levels pre and post-lenzilumab treatment (Day -1 and Day 2) in a patient with severe COVID-19 pneumonia J o u r n a l P r e -p r o o f
Clinical features of patients infected with 2019 novel coronavirus in Wuhan
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Cytokine release syndrome in severe COVID-19
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor Tcell Therapy for Acute Lymphoblastic Leukemia
Chimeric Antigen Receptor Therapy
How I treat hemophagocytic lymphohistiocytosis in the adult patient
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Toxicities of chimeric antigen receptor T cells: recognition and management
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center
The laboratory tests and host immunity of COVID-19 patients with different severity of illness
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis
Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Improved anti-tumor response of chimeric antigen receptor t cell (CART) therapy after GM-CSF inhibition is mechanistically supported by a novel direct interaction of GM-CSF with activated CARTs
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML)
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Covid-19: risk factors for severe disease and death
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention
Acknowledgements: Lenzilumab was provided by Humanigen, Inc. This work was supported through grants from K12CA090628 (SSK), Mayo Clinic K2R Career Development Program (SSK), ADB is supported by Grants AI 110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic.Disclosures: SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis) and Mettaforge (through Mayo Clinic). RS and SSK RS are inventors on patents in the field of CAR immunotherapy that are licensed to Humanigen (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, and Lentigen. SSK has participated in advisory boards with Kite, Juno, Novartis, and Humanigen. ADB is a consultant for Abbvie, is on scientific advisory boards for Nference and Zentalis, and is founder and President of Splissen therapeutics. The remaining authors declare no relevant disclosures.J o u r n a l P r e -p r o o f
Lenzilumab use was associated with faster improvement in clinical status and oxygenation, as well as greater reductions in inflammatory markers and markers of severity compared to the matched cohort. Lenzilumab was well tolerated; no treatment-emergent adverse events attributable to lenzilumab were observed.